These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36705970)

  • 21. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
    Koychev I; Hofer M; Friedman N
    J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retinal changes in Alzheimer's disease- integrated prospects of imaging, functional and molecular advances.
    Gupta VB; Chitranshi N; den Haan J; Mirzaei M; You Y; Lim JK; Basavarajappa D; Godinez A; Di Angelantonio S; Sachdev P; Salekdeh GH; Bouwman F; Graham S; Gupta V
    Prog Retin Eye Res; 2021 May; 82():100899. PubMed ID: 32890742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic delivery of a specific antibody targeting the pathological N-terminal truncated tau peptide reduces retinal degeneration in a mouse model of Alzheimer's Disease.
    Latina V; Giacovazzo G; Cordella F; Balzamino BO; Micera A; Varano M; Marchetti C; Malerba F; Florio R; Ercole BB; La Regina F; Atlante A; Coccurello R; Di Angelantonio S; Calissano P; Amadoro G
    Acta Neuropathol Commun; 2021 Mar; 9(1):38. PubMed ID: 33750467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amyloid Beta Immunoreactivity in the Retinal Ganglion Cell Layer of the Alzheimer's Eye.
    Lee S; Jiang K; McIlmoyle B; To E; Xu QA; Hirsch-Reinshagen V; Mackenzie IR; Hsiung GR; Eadie BD; Sarunic MV; Beg MF; Cui JZ; Matsubara JA
    Front Neurosci; 2020; 14():758. PubMed ID: 32848548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In Vivo Assessment of Retinal Biomarkers by Hyperspectral Imaging: Early Detection of Alzheimer's Disease.
    More SS; Beach JM; McClelland C; Mokhtarzadeh A; Vince R
    ACS Chem Neurosci; 2019 Nov; 10(11):4492-4501. PubMed ID: 31603648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer's disease.
    Shah TM; Gupta SM; Chatterjee P; Campbell M; Martins RN
    Mol Psychiatry; 2017 Mar; 22(3):353-363. PubMed ID: 28093567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's Retinopathy: Seeing Disease in the Eyes.
    Mirzaei N; Shi H; Oviatt M; Doustar J; Rentsendorj A; Fuchs DT; Sheyn J; Black KL; Koronyo Y; Koronyo-Hamaoui M
    Front Neurosci; 2020; 14():921. PubMed ID: 33041751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retinal imaging and Alzheimer's disease: a future powered by Artificial Intelligence.
    Ashayeri H; Jafarizadeh A; Yousefi M; Farhadi F; Javadzadeh A
    Graefes Arch Clin Exp Ophthalmol; 2024 Aug; 262(8):2389-2401. PubMed ID: 38358524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.
    Hampel H; Bürger K; Teipel SJ; Bokde AL; Zetterberg H; Blennow K
    Alzheimers Dement; 2008 Jan; 4(1):38-48. PubMed ID: 18631949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ocular amyloid imaging at the crossroad of Alzheimer's disease and age-related macular degeneration: implications for diagnosis and therapy.
    Ong SS; Proia AD; Whitson HE; Farsiu S; Doraiswamy PM; Lad EM
    J Neurol; 2019 Jul; 266(7):1566-1577. PubMed ID: 30155741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer's disease.
    Goozee KG; Shah TM; Sohrabi HR; Rainey-Smith SR; Brown B; Verdile G; Martins RN
    Br J Nutr; 2016 Feb; 115(3):449-65. PubMed ID: 26652155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alzheimer's disease amyloid-β pathology in the lens of the eye.
    Moncaster JA; Moir RD; Burton MA; Chadwick O; Minaeva O; Alvarez VE; Ericsson M; Clark JI; McKee AC; Tanzi RE; Goldstein LE
    Exp Eye Res; 2022 Aug; 221():108974. PubMed ID: 35202705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deep Reinforcement Learning-Based Retinal Imaging in Alzheimer's Disease: Potential and Perspectives.
    Hui HYH; Ran AR; Dai JJ; Cheung CY
    J Alzheimers Dis; 2023; 94(1):39-50. PubMed ID: 37212112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood-based Aβ42 increases in the earliest pre-pathological stage before decreasing with progressive amyloid pathology in preclinical models and human subjects: opening new avenues for prevention.
    Botella Lucena P; Vanherle S; Lodder C; Gutiérrez de Ravé M; Stancu IC; Lambrichts I; Vangheluwe R; Bruffaerts R; Dewachter I
    Acta Neuropathol; 2022 Sep; 144(3):489-508. PubMed ID: 35796870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice.
    Liu B; Rasool S; Yang Z; Glabe CG; Schreiber SS; Ge J; Tan Z
    Am J Pathol; 2009 Nov; 175(5):2099-110. PubMed ID: 19834067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances.
    Chong JR; Ashton NJ; Karikari TK; Tanaka T; Schöll M; Zetterberg H; Blennow K; Chen CP; Lai MKP
    J Neurol Neurosurg Psychiatry; 2021 Nov; 92(11):1231-1241. PubMed ID: 34510001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology.
    Ashton NJ; Brum WS; Di Molfetta G; Benedet AL; Arslan B; Jonaitis E; Langhough RE; Cody K; Wilson R; Carlsson CM; Vanmechelen E; Montoliu-Gaya L; Lantero-Rodriguez J; Rahmouni N; Tissot C; Stevenson J; Servaes S; Therriault J; Pascoal T; Lleó A; Alcolea D; Fortea J; Rosa-Neto P; Johnson S; Jeromin A; Blennow K; Zetterberg H
    JAMA Neurol; 2024 Mar; 81(3):255-263. PubMed ID: 38252443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.